A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Pamiparib (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Sponsors BeiGene
- 12 Nov 2019 According to the BeiGene media release, data from this study is expected in 2020.
- 13 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 27 May 2019 Planned primary completion date changed from 31 Mar 2020 to 30 Apr 2020.